|
|
|
|
|
|
by acveilleux
3930 days ago
|
|
|
Mandatory release is useful. At least Phase 3 and 4 trials conclusions should probably require publication. Phase 2 is less essential, drug will never go for sale without a Phase 3. Just saying "nope, won't continue with drug" in a press release doesn't really explain why. However, I think Phase 2 trials for new use of already approved compound should have a minimum publication requirement if they don't follow on to a phase 3. The safety (side effects and adverse events) should at least get aired. |
|
|